Protocol for an open randomised controlled trial investigating Fibrin Glue in Skin grafts for Skin cancer (FiGSS).


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
08 11 2022
Historique:
entrez: 9 11 2022
pubmed: 10 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

Skin cancer is a common disease in the tropics, and oncological resection typically requires reconstruction with skin grafts. Fibrin glue, initially established as a haemostatic agent, has been studied extensively as an adhesive for skin grafts in burns. This study aims to investigate the use of fibrin as an adhesive for split skin grafts in skin cancers. The study design is a prospective randomised controlled trial with the aim of investigating the impact of two different methods of split skin graft fixation. The intervention of fibrin glue will be compared with the control of staples or sutures. The trial will be conducted at two sites, a public hospital and a private hospital in Townsville, Australia, over a 24-month period with 334 participants to be recruited. Consecutive patients presenting for skin excisions and grafting will be eligible to participate in this study. Randomisation will be on the level of the patient. The primary outcome is graft take based on wound healing at 1 month. Secondary outcomes will be pain on dressing changes and operative time. The study has been approved by The Townsville University Hospital Human Research Ethics Committee. Findings will be disseminated in conference presentations and journals and through online electronic media. ACTRN12618000484246.

Identifiants

pubmed: 36351733
pii: bmjopen-2022-064431
doi: 10.1136/bmjopen-2022-064431
pmc: PMC9644346
doi:

Substances chimiques

Fibrin Tissue Adhesive 0

Banques de données

ANZCTR
['ACTRN12618000484246']

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e064431

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
Int J Dermatol. 2002 Oct;41(10):652-8
pubmed: 12390187
Eur Surg Res. 1994;26(5):273-6
pubmed: 7835384
Aust J Gen Pract. 2022 Mar;51(3):173-177
pubmed: 35224588
J Anesth. 2011 Jun;25(3):426-30
pubmed: 21424902
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Med J Aust. 1990 Nov 5;153(9):511-5
pubmed: 2233471
Med J Aust. 2006 Feb 20;184(4):162-4
pubmed: 16489899
Trop Med Infect Dis. 2021 Nov 09;6(4):
pubmed: 34842831
Scand J Plast Reconstr Surg Hand Surg. 1987;21(3):245-8
pubmed: 2450397
Lab Invest. 1987 Dec;57(6):673-86
pubmed: 2447383
Blood Rev. 1991 Dec;5(4):240-4
pubmed: 1782483
Plast Reconstr Surg. 1999 Dec;104(7):2100-7
pubmed: 11149774
BMJ. 2006 May 6;332(7549):1053-6
pubmed: 16636023
Clin Med (Lond). 2007 Jun;7(3):283-90
pubmed: 17633952
Clin Dermatol. 2005 Jul-Aug;23(4):343-52
pubmed: 16023929
World J Surg. 2010 Apr;34(4):632-4
pubmed: 19820991
Ann Otolaryngol Chir Cervicofac. 1992;109(2):95-9
pubmed: 1524366
J Burn Care Rehabil. 1997 Sep-Oct;18(5):429-34
pubmed: 9313125
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD004835
pubmed: 19821334
Plast Reconstr Surg. 1999 Jan;103(1):202-6
pubmed: 9915185
Br J Dermatol. 2002 Apr;146 Suppl 61:1-6
pubmed: 11966724
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
J Burn Care Res. 2008 Mar-Apr;29(2):293-303
pubmed: 18354285
Neurol Med Chir (Tokyo). 2008 Jan;48(1):30-2
pubmed: 18219190
Plast Reconstr Surg. 1992 Feb;89(2):268-71
pubmed: 1732894
J Burn Care Rehabil. 1993 May-Jun;14(3):356-8
pubmed: 8360243
Ann Thorac Surg. 1984 Oct;38(4):409-10
pubmed: 6333220
Ann Med Surg (Lond). 2020 Jun 12;56:48-55
pubmed: 32577231
Plast Reconstr Surg. 2001 Nov;108(6):1713-26
pubmed: 11711954
Burns. 1992 Oct;18(5):395-400
pubmed: 1445630
Drugs Aging. 2001;18(8):607-20
pubmed: 11587247
Aust J Gen Pract. 2018 Mar;47(3):153-157
pubmed: 29621848
Medicine (Baltimore). 2020 Jun 19;99(25):e20573
pubmed: 32569183
Br J Cancer. 1970 Jun;24(2):235-52
pubmed: 5451567
Paediatr Anaesth. 2013 Aug;23(8):754-6
pubmed: 23746210

Auteurs

Ekta Paw (E)

College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia ekta.paw@my.jcu.edu.au.

Venkat Vangaveti (V)

College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.

Mark Zonta (M)

Department of Surgery, Townsville University Hospital, Townsville, Queensland, Australia.

Clare Heal (C)

College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH